Atopic dermatitis and skin diseaseTight junction defects in patients with atopic dermatitis
Section snippets
Study participants: Expression profiling and validation experiments
The diagnosis of AD was made using the US consensus conference criteria.36 All patients with AD had extrinsic disease, as defined by a serum total IgE level 2 SDs or more of age-dependent norms and a positive multiallergen RAST result (ImmunoCap Phadiatop). Nonatopic healthy subjects were defined as having no personal or family history of atopic diseases, no personal history of chronic skin or systemic diseases, and a serum total IgE level that was 2 SDs or less of age-dependent norms and a
Claudin-1 expression is markedly reduced in nonlesional AD epidermis
To characterize and quantify the expression of human epidermal proteins important for barrier function, we performed gene expression profiling of nonlesional or clinically unaffected epidermis by using blister roofs from patients with AD, patients with psoriasis, and nonatopic subjects (Fig 2, B-D). The Illumina Sentrix HumanRef-8 Chip contained 43 TJ genes (see Table E2 in this article's Online Repository at www.jacionline.org), 8 gap junction genes, and 41 epidermal differentiation complex
Discussion
This is the first report, to our knowledge, implicating a TJ defect in patients with AD, a human skin disease that affects up to 15 million Americans. We demonstrated reduced expression of epidermal claudin-1 in AD nonlesional epidermis (Figs 2 and 3). This was specific for AD and not observed in patients with psoriasis, a TH17-driven inflammatory skin disorder (Fig 2). Although previous psoriasis publications have suggested that TJs might be altered in lesional epidermis, this has not been
References (87)
- et al.
The prevalence of atopic dermatitis in Oregon schoolchildren
J Am Acad Dermatol
(2000) The epithelium takes centre stage in asthma and atopic dermatitis
Trends Immunol
(2007)- et al.
Assessment of epidermal barrier function by photoacoustic spectrometry in relation to its importance in the pathogenesis of atopic dermatitis
Lab Invest
(2002) Barrier function of the skin: “la raison d′être” of the epidermis
J Invest Dermatol
(2003)Lipid abnormalities in atopic dermatitis
J Am Acad Dermatol
(2001)- et al.
Abnormal expression of sphingomyelin acylase in atopic dermatitis: an etiologic factor for ceramide deficiency?
J Invest Dermatol
(1996) - et al.
Aberrant lipid organization in stratum corneum of patients with atopic dermatitis and lamellar ichthyosis
J Invest Dermatol
(2001) - et al.
Cytokine modulation of atopic dermatitis filaggrin skin expression
J Allergy Clin Immunol
(2009) - et al.
The different structures containing tight junction proteins in epidermal and other stratified epithelial cells, including squamous cell metaplasia
Eur J Cell Biol
(2007) - et al.
ZO-1 and ZO-2 independently determine where claudins are polymerized in tight-junction strand formation
Cell
(2006)
Tight junctions/adherens junctions: basic structure and function
J Invest Dermatol
Claudin-based barrier in simple and stratified cellular sheets
Curr Opin Cell Biol
Sealing the live part of the skin: the integrated meshwork of desmosomes, tight junctions and curvilinear ridge structures in the cells of the uppermost granular layer of the human epidermis
Eur J Cell Biol
Epidermal tight junctions: ZO-1 and occludin are expressed in mature, developing, and affected skin and in vitro differentiating keratinocytes
J Invest Dermatol
Clinical severity correlates with impaired barrier in filaggrin-related eczema
J Invest Dermatol
Functional specializations of human epidermal Langerhans cells and CD14+ dermal dendritic cells
Immunity
Statistical issues with microarrays: processing and analysis
Trends Genet
Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method
Methods
Detection of the chemokine RANTES and endothelial adhesion molecules in nasal polyps
J Allergy Clin Immunol
Basal detachment of the epidermis using dispase: tissue spatial organization and fate of integrin alpha 6 beta 4 and hemidesmosomes
J Invest Dermatol
Selecting a maximally informative set of single-nucleotide polymorphisms for association analyses using linkage disequilibrium
Am J Hum Genet
Illumina universal bead arrays
Methods Enzymol
Tight junctions and tight junction proteins in mammalian epidermis
Eur J Pharm Biopharm
Organization and formation of the tight junction system in human epidermis and cultured keratinocytes
Eur J Cell Biol
Tight junctions and compositionally related junctional structures in mammalian stratified epithelia and cell cultures derived therefrom
Eur J Cell Biol
Altered tight junction structure contributes to the impaired epithelial barrier function in ulcerative colitis
Gastroenterology
Regulation of tight junction permeability by sodium caprate in human keratinocytes and reconstructed epidermis
Biochem Biophys Res Commun
Claudins regulate the intestinal barrier in response to immune mediators
Gastroenterology
Epidermal growth factor receptor activation differentially regulates claudin expression and enhances transepithelial resistance in Madin-Darby canine kidney cells
J Biol Chem
IL-4 suppresses the recovery of cutaneous permeability barrier functions in vivo
J Invest Dermatol
Alteration of tight junction proteins is an early event in psoriasis: putative involvement of proinflammatory cytokines
Am J Pathol
Claudin-1 gene mutations in neonatal sclerosing cholangitis associated with ichthyosis: a tight junction disease
Gastroenterology
Global variations in prevalence of eczema symptoms in children from ISAAC Phase Three
J Allergy Clin Immunol
Epithelial tight junctions in intestinal inflammation
Ann N Y Acad Sci
Epithelium dysfunction in asthma
J Allergy Clin Immunol
Skin-derived TSLP triggers progression from epidermal-barrier defects to asthma
PLoS Biol
Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis
Nat Genet
New perspectives on epidermal barrier dysfunction in atopic dermatitis: gene-environment interactions
J Allergy Clin Immunol
A nonsynonymous substitution of cystatin A, a cysteine protease inhibitor of house dust mite protease, leads to decreased mRNA stability and shows a significant association with atopic dermatitis
Allergy
The epidermal barrier function is dependent on the serine protease CAP1/Prss8
J Cell Biol
Multifunctional strands in tight junctions
Nat Rev Mol Cell Biol
Claudins and epithelial paracellular transport
Annu Rev Physiol
Tight junctions and cell-cell interactions
Methods Mol Biol
Cited by (550)
Immunomodulatory and anti-angiogenesis effects of excavatolide B and its derivatives in alleviating atopic dermatitis
2024, Biomedicine and PharmacotherapyBenvitimod Inhibits IL-4– and IL-13–Induced Tight Junction Impairment by Activating AHR/ARNT Pathway and Inhibiting STAT6 Phosphorylation in Human Keratinocytes
2024, Journal of Investigative DermatologyDevelopment of an ex vivo porcine skin model for the preclinical evaluation of subcutaneously injected biomacromolecules
2023, International Journal of Pharmaceutics
Supported by the Atopic Dermatitis and Vaccinia Network NIH/NIAID (contract N01 AI40029 and N01 AI40033), the National Eczema Association (A.D., L.A.B.), and the Mary Beryl Patch Turnbull Scholar Program (K.C.B.).
Disclosure of potential conflict of interest: A. De Benedetto has received research support from the National Eczema Association and the National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (NIAID). N. M. Rafaels has received research support from the NIH/NIAID. C. Cheadle has received research support from the NIH/NIAID. T. Yoshida has received research support from the NIH/NIAID. M. Boguniewicz has received research support from the NIH/NIAID. J. M. Hata has received research support from the NIH/NIAID. L. C. Schneider has received research support from Astellas and Novartis. J. M. Hanifin has received consulting fees from Johnson & Johnson and Otsuka Pharmaceutical Co and has received research support from Astellas Pharma US, Basilea, Novartis, Shionogi USA, the NIH/NIAID, and Taisho. R. L. Gallo has received research support from the NIH/NIAID. N. Novak has received research support from the German Research Council and the NIH/NIAID. T. H. Beaty has received research support from the NIH/NIAID. D. Y. M. Leung has received research support from the NIH/NIAID. K. C. Barnes has received research support from the NIH and Sanofi-Aventis. L. A. Beck has consulted for Regeneron, has received research support from the NIH/NIAID and the National Eczema Association. The rest of the authors have declared that they have no conflict of interest.